Boston Scientific Beats Expectations In Q1

Among the company's many milestones in the first quarter, the FDA approved its Therasphere radiation seed device, a major building block of the company's interventional oncology business.

Earning Report Q1

Boston Scientific’s revenues are recovering faster than the company predicted they would

For the first quarter of 2021, the company reported net sales of $2.75bn, representing a 5.9% year-over-year increase on an organic basis. In February, Boston Scientific told investors to expect...

More from Cardiology

More from Device Area